Loading…
Mono Pharmacare (MONOPHARMA)₹10.00+2.56%Pharmaceuticals
In the Mar 2026 quarter (consolidated), Mono Pharmacare reported sales of ₹98.88 Cr, up 22.1% from Mar 2025, and net profit of ₹0 Cr, down 100.0% year on year. For the year to Mar 2026, sales were ₹166 Cr and net profit ₹0 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 34.96 | 66.94 | 55.99 | 86.96 | 80.99 | 65.97 | 98.88 |
| Expenses | 33.06 | 63.12 | 53.13 | 82.13 | 78.14 | 65.15 | 97.23 |
| Operating Profit | 2.01 | 4.01 | 2.01 | 5.02 | 3.01 | 2.01 | 2.01 |
| OPM % | 6.0% | 6.0% | 4.4% | 5.0% | 3.6% | 2.7% | 2.2% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.00 | 0.00 |
| Interest | 1.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.99 | 1.99 | 0.99 | 2.99 | 0.99 | 0.00 | 0.00 |
| Tax % | 39.1% | 20.1% | 33.1% | 27.1% | 37.1% | 83.1% | 29.1% |
| Net Profit | 1.01 | 2.01 | 1.01 | 2.01 | 1.01 | 0.00 | 0.00 |
| EPS (Rs) | 0.51 | 1.05 | 0.32 | 1.29 | 0.45 | 0.00 | 0.18 |
| Mar 2023 6m | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 32.96 | 122 | 168 | 166 |
| Expenses | 31.04 | 116 | 161 | 162 |
| Operating Profit | 2.01 | 6.02 | 8.03 | 4.01 |
| OPM % | 7.0% | 5.0% | 4.5% | 2.4% |
| Other Income | 0.00 | 0.00 | 0.99 | 0.00 |
| Interest | 1.01 | 3.01 | 4.01 | 3.01 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.99 | 2.99 | 3.99 | 0.99 |
| Tax % | 29.1% | 24.1% | 30.1% | 40.1% |
| Net Profit | 1.01 | 2.01 | 3.01 | 0.00 |
| EPS (Rs) | 0.75 | 1.37 | 1.74 | 0.19 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 11.95 | 17.93 | 17.93 | 17.94 |
| Reserves | 1.01 | 10.03 | 14.03 | 14.03 |
| Borrowings | 40.11 | 41.13 | 54.13 | 56.12 |
| Other Liabilities | 8.97 | 11.98 | 24.98 | 34.10 |
| Total Liabilities | 63.04 | 81.07 | 110 | 122 |
| Fixed Assets | 0.99 | 0.99 | 0.99 | 0.99 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.99 | 0.00 | 0.00 | 0.00 |
| Other Assets | 61.06 | 80.08 | 109 | 121 |
| Inventories | 32.96 | 41.92 | 54.91 | 41.95 |
| Trade receivables | 21.98 | 31.95 | 41.97 | 74.96 |
| Cash & equivalents | 0.00 | 0.00 | 0.99 | 0.99 |
| Total Assets | 63.04 | 81.07 | 110 | 122 |
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Cash from operating activity | −39.93 | −8.99 | −3.99 |
| Cash from investing activity | −0.99 | 0.00 | 0.00 |
| Cash from financing activity | 40.97 | 8.01 | 4.99 |
| Net cash flow | 0.00 | 0.00 | 0.00 |
| Capex | 0.58 | 0.17 | 0.22 |
| Free cash flow | −39.93 | −8.98 | −4.99 |
| CFO / OP % | −1,765.0% | −126.0% | −38.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor days | 240 | 93 | 90 | 164 |
| Inventory days | 407 | 138 | 132 | 98 |
| Days payable | 87 | 32 | 45 | 68 |
| Cash conversion cycle | 563 | 202 | 179 | 196 |
| Working capital days | 299 | 131 | 120 | 126 |
| ROCE % | — | 10.0% | 11.0% | 5.0% |
For the Mar 2026 quarter, Mono Pharmacare reported sales of ₹98.88 Cr, up 22.1% year on year and net profit of ₹0 Cr, down 100.0% year on year. The operating margin was 2.2%.
Mono Pharmacare's sales for the year to Mar 2026 were ₹166 Cr.
Net profit for the year to Mar 2026 was ₹0 Cr. Earnings per share over the same trailing period were ₹0.19.
Mono Pharmacare reported borrowings of ₹56.12 Cr at Mar 2026, against cash and equivalents of ₹0.99 Cr.
Cash from operations was −₹3.99 Cr in the year to Mar 2025; after capital spending, free cash flow was −₹4.99 Cr.